Plus Therapeutics, Inc. (PSTV) Stock Price, Financials & Summary

Price chart

Jul 29Aug 3Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.8x

Market Cap

$26.64M

MomentumView details →

1D Return

−3.25%

YTD Return

−75.80%

RSI (14)

37.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.8x

Market Cap

$26.64M

RSI (14)

37.2

MomentumView details →

1D Return

−3.25%

YTD Return

−75.80%

SummaryUpdated Jun 1, 2026

Plus Therapeutics, Inc. (NASDAQ:PSTV) is a clinical-stage pharmaceutical company founded in 1996 and headquartered in Austin, Texas. Originally established as Cytori Therapeutics, Inc., the company changed its name to Plus Therapeutics in July 2019 to reflect its strategic pivot toward oncology treatments. The company has undergone significant transformation from its early focus on regenerative medicine to becoming a specialized developer of radiotherapeutic treatments for central nervous system cancers. Plus Therapeutics went public in 2001 and currently operates as a clinical-stage biotechnology company focused on addressing some of the most challenging cancers affecting the brain and spinal cord.

Ask drillr about Plus Therapeutics, Inc. →

ProfitabilityView details →

Gross Margin

61.53%

Net Margin

−620.70%

EBITDA Margin

−536.31%

ROE (TTM)

−477.54%

ROA (TTM)

−185.94%

Asset Turnover

0.25x

GrowthView details →

Revenue YoY

−20.95%

EPS YoY

+97.52%

FCF YoY

−39.38%

Revenue CAGR 3Y

+185.50%

EPS CAGR 3Y

+85.25%

EBITDA YoY

−56.71%

EarningsView details →

EPS (Actual)

−$1.05

EPS Surprise

−10.53%

Beats (12Q)

5/12

Next Q EPS Est

—

Avg Surprise (4Q)

19.54%

Rev Surprise

5.68%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

1.37x

Quick Ratio

1.37x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

4.20M

Net Income (TTM)

−26.09M

Op. CF (TTM)

−22.18M

Latest newsMore news →

CNSide Diagnostics, a subsidiary of Plus Therapeutics, signed a national coverage agreement with Elevance Health to provide the CNSide CSF TCE assay to approximately 45.4 million people in the United States.72d ago

Similar companies

TScan Therapeutics, Inc.TCRX Evaxion Biotech A/SEVAX ABVC BioPharma, Inc.ABVC Tvardi Therapeutics, Inc.TVRD BeyondSpring Inc.BYSI Estrella Immunopharma, Inc.ESLA Find similar companies →

Latest newsMore news →

Plus Therapeutics subsidiary CNSide Diagnostics signed a regional coverage agreement with Medical Mutual to provide the CNSide CSF TCE assay to approximately 1.2 million people in Ohio and Kentucky.46d ago CNSide Diagnostics, a subsidiary of Plus Therapeutics, signed a national coverage agreement with Elevance Health to provide the CNSide CSF TCE assay to approximately 45.4 million people in the United States.72d ago Plus Therapeutics' subsidiary CNSide Diagnostics received CAP accreditation for its Houston clinical laboratory.93d ago